Abbott Laboratories raised its full-year earnings forecast

Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts’ estimates, powered by higher sales across its businesses.

The diversified healthcare company on Wednesday reported an 11.3 percent rise in second-quarter medical device sales to $2.89 billion, topping analysts’ average estimate of $2.66 billion, reports Reuters.

The unit – the largest contributor to total sales with a 37 percent share – benefited from the increased adoption of the company’s sensor-based glucose monitoring system, FreeStyle Libre, which reduces the need for routine finger pricks for diabetics. The company’s rose 2.6 percent in premarket trading.

The Chicago-based company now expects adjusted earnings per share from continuing operations to be $2.85 to $2.91, compared with a prior range of $2.80 to $2.90.

Chief Executive Officer Miles White said he expected continued strong performance for the second half of the year and was confident of the outlook despite a strengthening U.S. dollar.

Sales outside the United States accounted for 65.2 percent of Abbott’s net sales in the quarter. Net earnings more than doubled to $733 million in the three months ended June 30.

Excluding items, the company earned 73 cents per share, ahead of analysts’ average estimate of 71 cents, according to Thomson Reuters I/B/E/S.

Overall, net sales rose 17 percent to $7.78 billion, beating estimate of $7.71 billion. Sales from the company’s diagnostics business jumped 47.2 percent to $1.87 billion, helped by sales of infectious disease and cholesterol tests that Abbott acquired as part of the Alere deal.

Have your say, we value it!

wise people got already engaged

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]

Translate this News

Popular Posts

Advertisement

Scroll Up